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Abstract
Background: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a
reduced incidence of Alzheimer's disease (AD). We and others have shown that certain NSAIDs reduce
secretion of Aβ42 in cell culture and animal models, and that the effect of NSAIDs on Aβ42 is independent
of the inhibition of cyclooxygenase by these compounds. Since Aβ42 is hypothesized to be the initiating
pathologic molecule in AD, the ability of these compounds to lower Aβ42 selectively may be associated
with their protective effect. We have previously identified R-flurbiprofen (tarenflurbil) as a selective Aβ42
lowering agent with greatly reduced cyclooxygenase activity that shows promise for testing this
hypothesis. In this study we report the effect of chronic R-flurbiprofen treatment on cognition and Aβ
loads in Tg2576 APP mice.
Results:  A four-month preventative treatment regimen with R-flurbiprofen (10 mg/kg/day) was
administered to young Tg2576 mice prior to robust plaque or Aβ pathology. This treatment regimen
improved spatial learning as assessed by the Morris water maze, indicated by an increased spatial bias
during the third probe trial and an increased utilization of a place strategy to solve the water maze. These
results are consistent with an improvement in hippocampal- and medial temporal lobe-dependent memory
function. A modest, though not statistically significant, reduction in formic acid-soluble levels of Aβ was
also observed. To determine if R-flurbiprofen could reverse cognitive deficits in Tg2576 mice where plaque
pathology was already robust, a two-week therapeutic treatment was given to older Tg2576 mice with the
same dose of R-flurbiprofen. This approach resulted in a significant decrease in Aβ plaque burden but no
significant improvement in spatial learning.
Conclusion: We have found that chronic administration of R-flurbiprofen is able to attenuate spatial
learning deficits if given prior to plaque deposition in Tg2576 mice. Given its ability to selectively target
Aβ42 production and improve cognitive impairments in transgenic APP mice, as well as promising data
from a phase 2 human clinical trial, future studies are needed to investigate the utility of R-flurbiprofen as
an AD therapeutic and its possible mechanisms of action.
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Background
Alzheimer's disease (AD) is the most common form of
dementia, and results in a progressive, irreversible decline
in memory and cognitive function. One of the pathologi-
cal hallmarks of the Alzheimer's brain is the presence of
aggregated amyloid beta (Aβ) peptide in extracellular pro-
teinaceous deposits in the parenchyma (senile plaques),
and cerebral blood vessels [1]. Aβ species with different
amino- and carboxyl-termini are constitutively produced
from the amyloid β precursor protein (APP) through
sequential proteolysis by β- and γ-secretases [2]. In most
cases, a 40 amino acid form of Aβ (Aβ40) is the major
secreted product of these cleavages. The 42 amino acid
form of Aβ (Aβ42), although secreted at much lower lev-
els than Aβ40, has been implicated as the initiating mole-
cule in the pathogenesis of AD [3].
Aβ42 is more amyloidogenic than Aβ40, and is deposited
earlier and more consistently than Aβ40 in the AD brain
parenchyma. Significantly, mutations in presenilin 1
(PS1), presenilin 2 (PS2), and APP genes linked to early
onset genetic forms of AD perturb Aβ peptide levels or in
rare cases directly alter the Aβ sequence in a way that
increase the propensity of the mutant Aβ to aggregate and
form fibrils. The vast majority of these AD-linked muta-
tions selectively increase the relative levels of Aβ42 pep-
tides (reviewed in [4,5]). Small shifts in Aβ42 production
have a tremendous impact on the development of AD. In
humans, AD-causing mutations in APP and PS elevate
plasma Aβ42 levels by 30%–100%, and are associated
with the onset of dementia in the 3rd to 5th decade of life
[6]. Studies of these same mutations in transgenic mice
also demonstrate that small increases in Aβ42 levels mark-
edly accelerate Aβ deposition in the brain and associated
pathologies [7,8]. More recent studies in transgenic mice
and Drosophila selectively expressing Aβ40 and Aβ42 in
the secretory pathway, demonstrates that Aβ42 but not
Aβ40 is sufficient to drive Aβ deposition, and, at least in
Drosophila, neurodegeneration [9,10].
Although numerous lines of evidence support a role for
Aβ42 in the underlying pathogenesis of AD, no therapies
in clinical use target this molecule. The only currently
approved treatments for AD are the acetylcholinesterase
inhibitors (donepizil, rivastigmine, galantamine) and the
N-methyl-D-aspartate receptor antagonist, memantine
[11]. These pharmacologic therapies are thought to
improve cognition by targeting specific symptoms of the
disease, such as reduced cholinergic neurotransmission
and increased glutamatergic activity leading to excess acti-
vation of NMDA receptors, respectively, without signifi-
cantly modifying the underlying disease pathology
[12,13]. Despite only modest symptomatic benefit,
cholinesterase inhibitors have been widely adopted for
clinical use in the early stages of AD, whereas memantine
has shown benefit in the moderate to severe stages of the
disease [14,15]. Given the growing AD epidemic there is
an urgent need to discover alternative, more effective,
therapies that not only target the disease symptoms but
can also slow or halt the underlying neurodegenerative
process. Several novel therapies based on the current
understanding of AD pathogenesis are being clinically
evaluated, including the use of anti-inflammatories [1].
Over the past 20 years, a substantial number of epidemi-
ological reports have shown that long-term use of non-
aspirin, nonsteroidal, anti-inflammatory drugs (NSAIDs)
is associated with protection from the development of AD
[16]. This data has been used to support the hypothesis
that anti-inflammatory drugs may be effective in slowing
the progression of disease, since a robust CNS inflamma-
tory response is another prevalent feature of AD [17].
Indeed, the epidemiologic data has been used as the pri-
mary rationale for previous and ongoing trials of select
NSAIDs in AD [18].
Results from these trials have been mixed. Clinical data
from one double-blind placebo-controlled trial showed
that indomethacin may improve cognition in dementia
[19], but the results from this study were confounded by
the lack of power and high drop-out rate due to adverse
effects of the drug. A prospective, 25-week, randomized,
double-blind placebo-controlled trial evaluating the effi-
cacy and safety of diclofenac in combination with misopr-
ostol in patients with mild to moderate AD in a
prospective, 25-week trial, did not demonstrate a signifi-
cant effect of NSAID treatment [20]. A more recent rand-
omized, placebo-controlled 1-year clinical trial of
naproxen or rofecoxib failed to detect any effect on cogni-
tive impairment by naproxen or rofecoxib administration
in mild to moderate AD patients [21]. Finally, because of
concerns over side-effects, a large prevention study (the
ADAPT trial) of naproxen and celecoxib was recently
halted [22,23].
There are a number of possible reasons for the varying
results from these trials, and one potential explanation
comes from studies which suggest that the general anti-
inflammatory activity of NSAIDs may play a secondary
role in modulating the development of Aβ pathology
while other pathways are involved [18]. First, chronic
administration of only certain NSAIDs in mice has been
reported to reduce Aβ deposition. Ibuprofen treatment
was shown to significantly reduce amyloid pathology,
neuritic dystrophy, plaque-associated gliosis and IL-1
expression in Tg2576 transgenic mice [24]. After 6
months of treatment, amyloid plaque numbers and Aβ
levels in brain were reduced almost 50% and 40%, respec-
tively. In the same study, naproxen treatment was not
effective. This result suggests that cyclooxygenase (COX)BMC Neuroscience 2007, 8:54 http://www.biomedcentral.com/1471-2202/8/54
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inhibition, the main target of NSAIDs, per se, is not driving
reductions in Aβ deposition. Furthermore, two nitric
oxide-releasing derivates of flurbiprofen (HCT 1026 and
NCX2216) and indomethacin have also been shown to
reduce amyloid pathology following long-term adminis-
tration to Aβ-depositing mice [25-27].
In contrast, nimesulide and celecoxib have been reported
to have no effect on Aβ plaque pathology, further suggest-
ing that COX 1 or 2 inhibition is not sufficient to decrease
Aβ deposition [27,28]. These results provide additional
evidence that only certain NSAIDs are able to suppress Aβ
aggregation in the brain and that these compounds may
be targeting a unique pathway.
One possible explanation for these observations is the dis-
covery that certain NSAIDs, such as ibuprofen, indometh-
acin, and the enantiomer of flurbiprofen are capable of
lowering the production of Aβ42 selectively [29,30]. In
contrast, certain COX-2 inhibitors selectively raise Aβ42
or have no effect [31]. The ability of these compounds to
modulate Aβ42 levels is independent of COX and other
previously identified targets of these drugs, such as NFκB
[32]. Although the mechanism of Aβ modulation has not
been definitively established, experimental evidence sug-
gests that these compounds target the γ-secretase complex
which is composed of PS1 or PS2, substrate (i.e. carboxyl-
terminal fragments of APP), and three essential accessory
proteins: nicastrin, APH-1, and PEN-2 [30,33-35].
The identification of compounds that selectively lower
Aβ42 provides a unique opportunity to test the hypothesis
that decreasing levels of this peptide will have a positive
impact on Aβ plaque pathology and cognition. Unfortu-
nately, the potential toxicity related to inhibition of COX
as well as diverse secondary targets of this class of drugs,
complicates efforts to experimentally test this hypothesis.
Extensive screening of NSAIDs, derivatives and related
compounds led to the identification of R-flurbiprofen as a
promising selective Aβ42-lowering agent that may cir-
cumvent some of these complications [30].
R-Flurbiprofen is a purified enantiomer of the classical
racemic NSAID, flurbiprofen, which displays minimal
COX activity and does not undergo stereoinversion in
humans [36,37]. Like the racemate, R-flurbiprofen retains
the ability to lower Aβ42 in cell culture and in the brain of
young non-depositing Tg2576 APP mice following 3-days
of oral dosing [30,38]. Based on R-flurbiprofen's selective
lowering of Aβ42, reduced COX activity and safety profile
in humans we have previously suggested that this drug
was a good candidate for clinical testing in AD [30].
Recently, a 1 year randomized, placebo-controlled, dou-
ble-blind Phase 2 study of R-flurbiprofen (MPC-7869,
Myriad Pharmaceuticals, Inc.) in 207 subjects with mild
to moderate AD (MMSE 15–26) was completed [39]. In
mild AD subjects (MMSE of 20–26) receiving the highest
dose of R-flurbiprofen (800 mg twice daily), statistically
significant benefit was observed in measures of activities
of daily living (ADCS-ADL; and global function (CDR-
sb), with positive trends in cognition (ADAS-cog). No
benefit was observed in moderate AD patients. In addi-
tion, R-flurbiprofen was generally well-tolerated in this
patient population. Phase 3 studies are currently ongoing
to further assess efficacy, safety, and the potential for this
compound to be a disease modifying agent.
In this study we report the effect of chronic R-flurbiprofen
treatment on cognition and Aβ loads in a transgenic
model of AD, Tg2576 APP mice. Tg2576 mice were gener-
ated as follows: male Tg2576 (C57BL/6.SJL, APP+/-) were
crossed with C57BL/6.SJL F1 females (APP-/-). These
crosses generated the F2 Tg2576 APP +/- mice (mixed
C57BL/6.SJL background), which were used in all experi-
ments. In two separate behavioural trials, long-term treat-
ment initiated in young Tg2576 mice with 10 mg/kg/day
R-flurbiprofen improved spatial learning as assessed by
the Morris water maze (WM). A modest reduction in bio-
chemical Aβ loads was also observed, though this did not
reach statistical significance in either study. A 2-week
treatment of older Tg2576 with the same dose of R-flurbi-
profen decreased Aβ plaque levels (p < 0.0001) but did
not result in any significant alteration in spatial learning.
Results
Chronic administration and brain levels of R-flurbiprofen 
in Tg2576 mice
Acute 3-day oral dosing of R-flurbiprofen in Tg2576 mice
is well-tolerated at doses up to 50 mg/kg/day. Maximal
brain Aβ42 lowering was observed with doses of 25–50
mg/kg/day, but doses of 10 mg/kg/day also lowered Aβ42
[30]. In these initial short-term dosing studies no mortal-
ity or morbidity was observed. However, initial pilot long-
term studies using dosing regimens designed to deliver
either 25 and 50 mg/kg day (see Methods) resulted in
85% and 100% mortality, respectively, within 2 weeks. A
10 mg/kg/day dose did not result in increased mortality
after 14 days, and was therefore chosen for long-term
studies. Experimental design, group sizes, and survival
data for each of the experiments designed to deliver ~10
mg/kg/day of R-flurbiprofen are shown in Tables 1 and 2.
R- and S-flurbiprofen levels in the brain of mice from one
water maze (Exp. 3) were analyzed using liquid chroma-
tography and mass spectrometry techniques and were
found to be 158 ± 14.7 and 76.0 ± 8.0 ng/gm brain tissue
respectively.BMC Neuroscience 2007, 8:54 http://www.biomedcentral.com/1471-2202/8/54
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Sensory and motor ability
For the behavioural analysis, the control groups were col-
lapsed across experiments as described in the statistical
analysis section, resulting in 3 groups for statistical analy-
sis: Control, Preventative ("Preventative", experiments 1
& 2) and Therapeutic ("Therapeutic", experiment 3)(see
Statistical Analysis section for further discussion of
groups). Assessment of sensory and motor ability was
determined by measuring the latency of mice to escape to
a visible platform and their swimming speed. Figure 1A
shows that there were no differences between groups in
escaping to the visible platform [F(2,55) = .61, ns]
although all groups became more proficient in escaping to
the visible platform over the course of the 6 training trials
[F(55,5) = 31.62, p < .0001]. Similar results were apparent
in the pathlength the mice took to reach the visible escape
platform, which showed no main effect of group [F(2,55)
= 1.23, ns] but a general decrease in distance travelled
with increased training [F(55,5) = 28.35, p < .0001, data
not shown]. Table 3 shows that mice treated with R-flur-
biprofen, regardless of length of administration, had
modest but significantly lower swimming speed [F(2,55)
= 4.11, p < .05].
Spatial reference memory
Figure 1B shows the search error in the acquisition of the
spatial reference memory task. All groups became more
proficient with increased training [F(55, 9) = 8.38, p <
.0001]. A significant interaction between training day and
group indicated that the groups differed on certain days
but there was no main effect of drug-treatment group
[F(2,55) = 1.16, ns]. Post hoc Fisher's PLSDs for each day
revealed the following differences: on day 4, there was a
significant difference between the Control and the Pre-
ventative group (p < .05); on days 7, 8, and 10 there was
a significant difference between the Therapeutic and the
Preventative R-flurbiprofen groups (p < .05); on day 9
there was a significant difference between the Control and
Therapeutic group (p < .05). The general pattern indicates
that the oldest group of mice that only received drug for 2
weeks (Therapeutic) performed more poorly than the
vehicle and 16-week R-flurbiprofen-treated (Preventative)
groups on the last few days of training trials. Similar
results were obtained with latency (day × group interac-
tion, F(2,55) = 1.77, p < .05) and pathlength measures
(day × group interaction, F(2,55) = 2.02, p < .01), data not
shown.
The spatial bias of the mice for the location of the hidden
escape platform is shown by the percent of time the mice
spent in the quadrant of the maze that contained the plat-
form during the three interpolated probe trials (Figure
1C). A main effect of group [F(2,55) = 3.91, p < .05] and
a significant interaction between group and probe trial
[F(4,110)= 6.52, p < .0001] indicates that the mice in the
Preventative R-flurbiprofen treatment group significantly
increased their spatial bias on the third probe trial (post
hoc one-way ANOVA (× Group) on Probe 3, [F(2,55) =
12.10, p < .0001]). The performance of the Preventative
group is significantly different from both the Control and
the Therapeutic group (Fisher's PLSD p's < .0005). Figure
1D shows representative swim paths of the control and
the Preventative group during the third probe trial. The
swimming paths of the R-flurbiprofen-treated mice dem-
onstrate a more localized search pattern over the location
of the hidden escape platform (bottom left quadrant),
indicating a well-formed spatial bias.
Strategy preference
In accordance with the increased spatial bias of the mice
on the R-flurbiprofen Preventive regimen, these mice also
show a significant preference for using a hippocampal-
Table 1: Experimental Design
Experiment Drug Regimen Age at Drug Onset Age at Behavioral Testing Age at Sacrifice
Experiment 1 Preventative 8 months 11½–12 months 15 months
Experiment 2 Preventative 8–9 months 11½–12 months 13 months
Experiment 3 Therapeutic 17 ½–18 months 18–19 months 19–20 months
Table 2: Subject
Water Maze Control Groups
Tg2575 mice not administered R-fluribiprofen
Drug Treatment Groups
Tg2576 mice administered 10 mg/kg R-flurbiprofen
Initial N Final N Died Failed Cue Training or Blind Initial N Final N Died Failed Cue Training or Blind
Exp. 1 18 13 32 1 3 11 02
Exp. 2 17 13 13 1 4 10 13
Exp. 3 15 12 03 1 5 13 11BMC Neuroscience 2007, 8:54 http://www.biomedcentral.com/1471-2202/8/54
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dependent place learning strategy compared to the Con-
trol and Therapeutic groups (χ2 = 11.23, p < .01), shown
in Figure 1E. The Control and the Therapeutic groups both
preferred the use of a cue response on the competition
test, thought to indicate the use of a striatal-based learning
strategy [40].
Assessment of Aβ loads
At the conclusion of behavioural testing, mice were sacri-
ficed and assessed for biochemical loads of Aβ using
sequential extraction first of detergent soluble Aβ fol-
lowed by formic acid (FA) soluble Aβ. Although both
groups of mice on the preventive dose of R-flurbiprofen
(experiments 1 & 2) displayed similar improvements of
spatial learning and were pooled for analysis of behav-
iour, they were aged for different lengths of time following
the end of water maze testing and were expected to have
different levels of Aβ deposition (see Table 1). Thus, these
groups were separated for biochemical analysis of Aβ lev-
els.
We observed no significant differences in detergent solu-
ble Aβ40 or Aβ42 levels between the treated and control
groups in experiments 1, 2 or 3 (Fig 2) as measured by
peptide specific sandwich ELISAs. In experiment 1, pre-
ventative  R-flurbiprofen treatment and sacrifice at 15
months of age resulted in a non-significant reduction in
FA Aβ40 (24%) and Aβ42 (23%) levels (Fig 2). In experi-
ment 2, a preventative R-flurbiprofen regime and sacrifice
at 13 months of age produced no change in Aβ40 levels
but a 34% decrease in the levels of FA Aβ42, which did not
reach significance (p < 0.25). In experiment 3, a 2-week
therapeutic treatment with R-flurbiprofen in 20-month-
old mice produced a non-significant lowering of Aβ40
(14%) and a significant lowering of Aβ42 (17%) (p <
0.05). Assessment of total Aβ plaque load using immuno-
histochemical quantification failed to reveal significant
differences after long-term R-flurbiprofen treatment
(experiment 2). In contrast, short-term treatment with R-
flurbiprofen at 20 months of age (experiment 3) resulted
in a significant decrease in Aβ plaque burden as measured
by the percent immunoreactive area (Fig 3C, p < 0.001).
Discussion and conclusion
We have found that chronic administration of R-flurbi-
profen is able to attenuate spatial learning deficits in
Tg2576 mice that began treatment at 8 months of age. The
improved spatial learning ability of the R-flurbiprofen-
treated mice was indicated by an increased spatial bias
during the third probe trial and the increased preference
for using a place strategy on the strategy preference test.
These results are consistent with an improvement in hip-
pocampal/medial temporal lobe-dependent memory
function [40]. A short 2-week administration of R-flurbi-
profen in 19-month-old Tg2576 mice with AD-like Aβ
loads had no effect on cognitive performance. Unfortu-
nately, long-term treatment of aged Tg2576 mice with the
same dose of R-flurbiprofen results in enhanced morbid-
ity and mortality (not shown), making it difficult to per-
form an experiment in which older mice are treated for
the same period of time.
Both long- and short-term treatment of Tg2576 mice with
R-flurbiprofen resulted in a decrease in the swim speed of
the mice. It is possible that the decrease in swim speed in
the  R-flurbiprofen-treated mice observed in this study
reflects a general effect of returning motor activity to nor-
mal levels in Tg2576 mice. Decreases in swim speed
reported in this study are unlikely to account for the
effects of R-flurbiprofen on our measures of hippocam-
pal-dependent memory as R-flurbiprofen was an effective
modulator of swim speed with both the Preventative and
Therapeutic treatment regimens but only the Preventative
treatment regimen increased spatial learning ability in the
Tg2576 mice.
R-flurbiprofen has been demonstrated to lower steady-
state Aβ42 levels after 3 days of oral administration in
Tg2576 mice [30]. In this study, however, the results indi-
cate that a preventative treatment strategy of R-flurbipro-
fen administration does not significantly alter soluble,
RIPA extracted-Aβ40 or 42 but does reduce insoluble, for-
mic acid-soluble Aβ levels 24–34%, although the decrease
is not statistically significant (Fig 2). Interestingly, the pre-
ventative treatment had no effect on plaque burden (Fig
3). These results contrast with the therapeutic, or short-
term, treatment in 18-month-old mice where formic-acid
soluble Aβ42 levels and the Aβ plaque burden was signif-
icantly decreased. The reduction in Aβ42 levels and
plaque burden did not improve spatial learning in the 18-
month-old mice. Clearly, these results indicate that the
length of time R-flurbiprofen is administered and the age
at which treatment is started are critical factors in produc-
ing beneficial effects on cognition. The relationship
between cognitive improvement and Aβ is controversial.
Improvement in spatial memory in Tg2576 mice has been
shown to occur using a preventative regime of ginko
biloba or alpha lipoic acid without a corresponding
change in Aβ levels or deposition [41,42]. In addition,
several studies now show that cognitive impairment in
Tg2576 mice and other APP mice does not correlate well
Table 3: Swim Speed
Group Swim Speed (m/sec ± SE)
Controls .191 ± .005
Preventative (Exp. 1 & 2) .169 ± .010*
Therapeutic (Exp. 3) .167 ± .008*
*p < .05 compared to Controls, Fisher's PLSDBMC Neuroscience 2007, 8:54 http://www.biomedcentral.com/1471-2202/8/54
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Sensory motor and spatial learning ability measured in the water maze Figure 1
Sensory motor and spatial learning ability measured in the water maze. 1A shows the latency to escape to the visi-
ble escape platform during cue training. There are no differences in the performance of any of the groups. 1B shows the search 
error during the acquisition of the spatial reference memory task. The 2-week R-flurbiprofen-treated mice (Therapeutic group) 
performed more poorly than the other groups (Preventative group) on days 4, 7, 8, 9 and 10. 1C shows that only the Tg2576 
mice treated for 16 weeks (Preventative group) with R-flurbiprofen developed a spatial bias for the training quadrant. 1D 
shows representative swim paths of the Control and the Preventative groups during Probe Trial 3. Note that the R-flurbipro-
fen-treated mice focus their search in the training quadrant that contained the hidden escape platform (bottom left quadrant). 
1E shows the percent of subjects that preferred using a cue or place strategy during the strategy competition. 80% of the 
Tg2576 mice in the Preventative group preferred using a place strategy compared to only 30% of the Control and 31% of the 
Therapeutic group (Chi-square = 11.23, p < .01).BMC Neuroscience 2007, 8:54 http://www.biomedcentral.com/1471-2202/8/54
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with Aβ deposition and may be attributable to small sol-
uble assemblies of Aβ [43,44]. Moreover, cognitive
improvement can be seen following anti-Aβ immuno-
therapy, even when there is no significant alteration in Aβ
deposition [45-49]. It is possible that delaying interven-
tions until pathology is well-developed may prevent func-
tionally significant changes in learning and memory due
to irreversible changes in synaptic transmission.
The reason that the two-week therapeutic-regimen in
older Tg2576 (19–20 month) did not lead to significant
behavioral improvement is not readily apparent. How-
ever, since it appears that chronic treatment with R-flurbi-
profen is necessary in Tg2576 mice for spatial learning
augmentation, it seems unlikely that the drug is working
through the same mechanism as the anti-Aβ antibodies,
which have been reported to work rapidly [48]. Further-
more, our more recent experience with behavioral testing
of APP mice suggests that negative results be interpreted
cautiously, since assessment of the cognitive phenotype in
APP mice can be variable even among cohorts of mice
bred and housed in the same environment (unpublished
observations). Moreover, it is possible that behavioral
testing and analysis of Tg2576 mice itself alters Aβ burden
since it has been shown that enrichment paradigms, such
as access to running wheels, appear to be capable of alter-
ing Aβ deposition and cognition [50,51]. In future studies
it will be important to control for possible effects of
behavioral training on Aβ deposition by including
cohorts of treated and untreated mice that are not subject
to behavioral testing.
Effect of R-flurbiprofen treatment on amyloid-β plaques in  Tg2576 mice Figure 3
Effect of R-flurbiprofen treatment on amyloid-β 
plaques in Tg2576 mice. Brain sections of representative 
Control and R-flurbiprofen-treated mice from water maze 
Experiment 3 (20 months at sacrifice) were stained for Aβ 
plaques using antibody 33.1.1 (A) and thioflavin (B). In (C), 
the level of Aβ plaque burden (quantified as % Aβ immunore-
active area) in Control compared to R-flurbiprofen treated-
Tg2576 mice from Experiments 2 and 3 are compared. Note 
the significant reduction in plaque burden in the R-flurbipro-
fen treated mice from Experiment 3 (*** p < 0.0001).
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ELISA quantitation of Aβ levels in Tg2576 from water maze  experiments Figure 2
ELISA quantitation of Aβ levels in Tg2576 from 
water maze experiments. The levels of detergent soluble 
(RIPA or SDS) and formic acid soluble Aβ1–40 and Aβ1–42 
in R-flurbiprofen treated mice from the three water mazes 
are plotted as percent control. The mean Aβ levels +/- the 
standard error from control mice are shown below each 
graph. The absolute values (pmoles/gram tissue) of formic 
acid soluble Aβ40 and Aβ42 levels from individual animals 
are plotted against one another to show the distribution of 
individual animals from experimental groups. "Preventative 1 
and Preventative 2" refers to two different experiments 
examining the effects of 4 months of administration of R-flur-
biprofen to Tg2576 mice. "Therapeutic" refers to 2 weeks 
administration of R-flurbiprofen.
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In humans, R-flurbiprofen appears to be safe and is well-
tolerated, with relatively few side effects [39] and under-
goes minimal racemization to the S-enantiomer [36]. In
contrast, following oral administration to mice ~20–40%
of the R-flurbiprofen is converted to the S-enantiomer
(see Results; [52]). This conversion is likely to account for
toxicity observed upon chronic dosing regimens more
likely to alter Aβ42 production. Overall, our data demon-
strate a clear cognitive benefit of long-term administra-
tion, but are inconclusive with respect to the relationship
between effects on Aβ deposition and behavioural
improvements. Previous studies have shown that chronic
treatment with nitric oxide-releasing flurbiprofen deriva-
tives do lower Aβ accumulation in APP mice, but it is not
clear if this effect is due to the prodrug (which is not likely
to affect Aβ42 production) or flurbiprofen released fol-
lowing metabolism [27,53]. In this study we see trends
towards reduced Aβ deposition in the prevention studies
and small but significant decrease in Aβ deposition in the
therapeutic study.
Aβ42-lowering NSAIDs have been shown to affect multi-
ple pathways and targets that could alter the AD pheno-
type, any of which could contribute to their ability to
protect against the development of AD [18]. For instance,
certain NSAIDs reduce production of the more amy-
loidogenic Aβ peptide by altering γ-secretase cleavage of
APP [29,30]. While other NSAIDs have also been shown
to directly inhibit Aβ aggregation in vitro [54,55]. They
may also decrease BACE expression through activation of
PPARγ leading to decreased levels of Aβ [56]. In addition,
more classic anti-inflammatory activities against cycloox-
ygenase as well as additional non-intended target activi-
ties against lipoxygenase and NFk-β could mediate
beneficial effects [18]. In contrast, R-flurbiprofen is not a
classic NSAID in humans because it does not significantly
inhibit cycloxygenase enzymes; however, it is similar in
structure and could bind to other known targets of
NSAIDs as well as unknown targets. Given the data pre-
sented here which suggests that R-flurbiprofen improves
cognitive performance in APP mice it will be important in
future studies to further delineate the underling mecha-
nisms that contribute to efficacy of R-flurbiprofen as a
potential AD therapeutic.
Taken together, the results from this study show that
chronic treatment with R-flurbiprofen beginning at an
early stage of cognitive dysfunction maybe necessary to
improve learning impairments, at least in the Tg2576 APP
mouse model. An important caveat is that these results
were obtained using a sub-optimal dose of R-flurbiprofen,
which was necessitated by the toxicity of the compound at
higher doses in these mice, most likely caused by bioin-
version to S-flurbiprofen and the subsequent COX-medi-
ated gastrointestinal toxicity that is not seen in humans.
Thus, extrapolating this dosing paradigm and results to
human AD patients is difficult at best. The ongoing phase
3 clinical trial of R-flurbiprofen in mild AD patients
should provide the most conclusive test to date of the effi-
cacy of this drug, and the general strategy of selectively
lowering Aβ42, in modifying the underlying disease pro-
gression and associated cognitive decline in AD.
Methods
Animals
All animal husbandry and testing procedures performed
were approved by the Mayo Clinic Institutional Animal
Care and Use Committee in accordance with NIH guide-
lines. Female Tg2576 mice were generated and confirmed
by genotyping as described previously [57,58]. All ani-
mals were housed 3–5 to a cage and maintained on ad
libitum food and water with a 12-hour light/dark cycle in
a controlled environment. One week prior to and during
water maze testing animals were individually housed. R-
Flurbiprofen, at a concentration of 67, 167.5 or 335 or mg
per kg of diet was homogenously incorporated into Har-
lan Teklad 7012 kibble by Research Diets, Inc. Based upon
dietary consumption of diet at this age, these diets were
designed to result in 10, 25 or 50 mg R-flurbiprofen on
average per day. By monitoring daily consumption on the
dose designed to deliver 10 mg/kg/day, we estimate that
the mice received between 8–12 mg R-flurbiprofen per kg
body weight per day. Kibble consumption, general health
and body weight were monitored on a weekly basis. For
behavioral experiments, all mice were negative for the ret-
inal degeneration mutation that occurs in approximately
25% of the mice in our colony [59].
R-Flurbiprofen experiments
The mice were assigned to a "Preventative" or a "Thera-
peutic" experimental group based on age. R-Flurbiprofen
was administered at a concentration of 10 mg/kg/day for
all experiments. In the two "Preventative" experiments
(experiments 1 and 2), dosing was started at ages prior to
or early in the emergence of cognitive deficits, between 8
and 9 months of age, and treatment continued for 4
months. Treated and untreated mice were then assessed
for spatial learning ability in the Morris water maze at
approximately 12 months of age when learning deficits
are usually present (e.g. [43]). In a "Therapeutic" experi-
ment (experiment 3), Tg2576 mice were given 2 weeks of
R-flurbiprofen prior to water maze testing, starting at 18
months of age when Aβ levels have already increased and
cognitive deficits are normally present.
Spatial learning assessment
At the conclusion of the drug-treatment phase, mice were
assessed for spatial reference memory in the Morris water
maze. Subjects were maintained on their appropriate drug
regime during behavioral evaluation. The water maze wasBMC Neuroscience 2007, 8:54 http://www.biomedcentral.com/1471-2202/8/54
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chosen as the testing paradigm as spatial learning in the
water maze has been extensively used to measure hippoc-
ampal function and age-associated cognitive impairment
in rodents (e.g., [60]).
The water maze consists of a circular tank (4-ft dia) with a
removable escape platform centered in one of the four
maze quadrants. During testing, the tank is filled with
25°C water clouded by non-toxic white paint. For training
trials, the top of the escape platform is submerged .05 cm
below the water surface. Black curtains with white pat-
terns surround the maze. Data are analyzed using a video
tracking system and software developed by Richard Baker,
HVS Image Analyzing (Hampton, U.K.).
Cue training occurs prior to hidden platform trials to test
for sensorimotor and motivational factors that may influ-
ence spatial learning. There is one day of cue training, con-
taining 6 trials. A visible black platform that extends 2 cm
from the water surface is moved to different locations in
the pool between trials and the subject's entry point into
the tank randomized. Each mouse is given 30 sec to reach
the platform and remains on the platform briefly. Trials
are separated by a 5–10 minute intertrial interval. Mice
that performed +/- three times the standard deviation
from the mean were excluded from further study. This
accounted for approximately 20% of the initial number of
mice. In addition, mice that exhibited stereotypic behav-
iour such as compulsive circling were also excluded from
behavioral analysis (< 1%).
For hidden platform training trials, there are 4 trials a day
for 10 days. The animal is placed in the water at the pool's
perimeter and allowed 60 seconds to locate the stationary
escape platform. These trials generate the search error
score that reflects the animal's distance from the platform
throughout their search. The search error reflects the
cumulative proximity of the mouse from the escape plat-
form during the training trial. The position of entry for the
animal is varied at each trial. There is a 5–10 minute inter-
trial interval. The first trial of training days 4, 7, and 10
consists of a 30 sec probe trial that serves to assess the
development of a spatially localized search for the escape
platform. During such trials, the escape platform is una-
vailable for escape.
Strategy preference was assessed 24 hours after the last day
of place training. A visible platform was placed in the
quadrant opposite the training quadrant where the hid-
den platform was previously located. The mice were given
two 60-second strategy probe trials. Start locations were
on either side of the tank, equidistant from the visible cue
platform and the prior hidden platform location. A "place
strategy" was recorded if the mouse crossed the annulus of
the prior hidden platform location before escaping to the
visible platform. The annulus was defined as a 5 cm
perimeter around the prior hidden escape platform loca-
tion. A "cue strategy" was recorded if the mouse did not
cross the prior hidden platform annulus before swimming
to the visible platform. Data was scored by observation of
recorded swim paths by the HVS Imaging program.
Analysis of flurbiprofen levels in brains of Tg2576 mice
Mouse hemibrains or cerebella were homogenized in two
volumes of HPLC-grade water (μL per mg) with a Turrax
T8 homogenizer followed by centrifugation of homoge-
nates at 2,000 g 4°C, for 10 min. Concentrations of R and
S-flurbiprofen in extracts were determined against
untreated brain extracts including drug standards, with a
range of quantification between 1–1,000 ng/ml using tan-
dem liquid chromatography-mass spectrometry-mass
spectrometry as previously described [31].
Methanol (200 μL) was used to precipitate proteins from
100  μL of brain homogenate followed by fortification
with an internal standard (deuterated racemic flurbipro-
fen). Samples were mixed for two minutes in a Captiva fil-
ter plate on a plate shaker before being transferred to a
vacuum apparatus. Vacuum (1 mm Hg) was applied for
three minutes and filtered extracts were collected in a new
96-well plate ready for LC-MS/MS analysis.
A calibration curve for the quantitative determination of
each compound was made in the range of 1 to1000 ng/
mL. Each 10× spiking solution (10 μL) was added to 90 μL
of blank mouse brain homogenate (prepared as above) to
generate the curve. Three QC samples were made at each
different concentration of 80, 320 and 800 ng/mL to
determine the validity of the calibration curve. Standard
curve and QC points were prepared in the same manner
as the samples for analysis.
Following sample preparation, 10 μL of sample extract
was injected onto a Daicel ChiralPAK AD-RH 4 × 150 mm
column and eluted at 0.55 mL/min using the following
isocratic mobile phase: 90% methanol, 5% acetonitrile,
5% water and 0.1% acetic acid. Compounds were detected
using an ABI 4000 Q-Trap linear ion trap mass spectrom-
eter in Multiple Reaction Monitoring mode with the fol-
lowing mass transitions monitored: m/z 243.3→199.1 for
7869 and S-flurbiprofen and m/z 246.3→202.1 for the
deuterated 7869 and S-flurbiprofen internal standard.
Analysis of Aβ levels in Tg2576 mice
Brains of mice were divided by midsagittal dissection after
sacrifice by CO2 asphyxiation. One hemibrain was fixed in
4% paraformaldehyde for immunohistochemical studies
and the other flash frozen in isopentane and used for bio-
chemical analysis as described previously [61]. Briefly,
each hemibrain (150 mg/ml wet wt) was extracted inBMC Neuroscience 2007, 8:54 http://www.biomedcentral.com/1471-2202/8/54
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either 1× RIPA buffer or 2% SDS with complete protease
inhibitor (Roche) using a PowerMax 200 homogenizer
(VWR), followed by centrifugation at 100,000 g for 1 hour
at 4°C. Following centrifugation, the supernatant was col-
lected, which represented the detergent-soluble fraction.
The resultant pellet was then extracted in 70% FA, using a
probe sonicator 3000 (Misonix), centrifuged at 100,000 g
for 1 hour at 4°C, and the supernatant collected. Extracted
Aβ was measured using a sandwich ELISA system utilizing
monoclonal antibodies developed at Mayo Clinic that has
been described before in detail [31,61]. To measure Aβ42
levels-peptides were captured with mAb 2.1.3 (specific for
the c-terminus of Aβ42) and detected with HRP-conju-
gated mAb Ab9 (specific for human Aβ1–16); To measure
Aβ40 levels peptides were captured with mAb Ab9 and
detected with HRP-conjugated mAb 13.1.1 (specific for
the c-terminus of Aβ40)
Immunohistology
Hemibrains of mice were fixed in 4% paraformaldehyde
in 0.1 M PBS (pH 7.6) and then stained for Aβ plaques as
described previously [61]. Paraffin sections (5 μm) were
pretreated with 80% FA for 5 minutes, boiled in water
using a rice steam cooker, washed, and immersed in 0.3%
H2O2 for 30 minutes to block intrinsic peroxidase activ-
ity. They were then incubated with 2% normal goat serum
in PBS for 1 hour, with 33.1.1 (Aβ1–16 mAb) at 1 μg/ml
dilution overnight, and then with HRP-conjugated goat
anti-mouse secondary mAb (1:500 dilution; Amersham
Biosciences) for 1 hour. Sections were washed in PBS, and
immunoreactivity was visualized by 3,3'-diaminobenzi-
dine tetrahydrochloride (DAB) according to the manufac-
turer's specifications (ABC system; Vector Laboratories).
Adjacent sections were stained with 4% thioflavin-S for 10
minutes. Fixed, paraffin-embedded sections were stained
for activated microglia using anti-Iba1 (1:3000; Wako
Chemicals) and for activated astrocytes using anti-GFAP
(1:1000, Chemicon).
Quantitation of amyloid plaque burden
Computer-assisted quantification of Aβ plaques was per-
formed in a blinded fashion as described previously [62].
Serial coronal sections were stained with 33.1.1 and
plaques were quantified (calculated as proportional area
of plaque burden) in the neocortex of the same plane of
section for each mouse (~10 sections per mouse) using
MetaMorph 6.1 software (Universal Imaging Corp,
Downington, PA).
Statistical analysis
Experiments 1 and 2 were replicate experiments investi-
gating the long-term treatment effects of R-flurbiprofen
on spatial memory. The results from the two studies par-
alleled each other, but the N was relatively small in exper-
iment 2 compared to experiment 1 (experiment 1, control
N = 12, R-flurbiprofen = 9; experiment 2, control = 6, R-
flurbiprofen = 6). There were no differences between the
12-month-old control mice from experiments 1 and 2 (N
= 18) when compared to the 19-month-old control mice
from experiment 3 (N = 12) on visible platform latency
[F(1,28) = .15, ns], hidden platform search error [F(1,28)
= .003, ns] or the percent time in training quadrant
[F(1,28) = .05, ns]. Therefore, for subsequent analysis of
the behavioral data, the control groups from all three
experiments were collapsed into one group for statistical
power and clarity of presentation. The final groups were:
vehicle control (N = 30), the collapsed group of experi-
ments 1 and 2 (16-week-R-flurbiprofen treatment, pre-
ventative regimen, N = 15) and experiment 3 (2-week-R-
flurbiprofen treated, therapeutic regimen, N = 15).
Repeated measures ANOVAs (× Group) were then used to
examine visible platform latency, hidden platform search
error and probe trial data. Significant interactions were
examined  post hoc by one-way ANOVAs and Fisher's
PLSDs. Chi-square analysis was done on the number of
subjects categorized as "place" or "cue" learners during
the strategy preference test. For presentation purposes,
this data was converted to the percent of subjects.
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